UK healthcare reform
18 November 2016 by
A deeper look at the UK’s Accelerated Access Review
19 July 2016 by Milena Izmirlieva
Pinpointing the exact impact of Brexit on healthcare spending and pharmaceutical spending remains a moving target
20 June 2016 by Milena Izmirlieva
9 November 2015 by Kavita Rainova
Is England's Cancer Drug Fund sustainable?
17 June 2015 by Maria McGee
Sweden looks to reform its pricing model.
15 June 2015 by Tania Rodrigues
Is global action needed to curb wide-spread use of antibiotics and the development of drug-resistant bacteria?
16 March 2015 by Kavita Rainova
As of 12 March, some of the drugs that were previously funded through the Cancer Drug’s Fund (UK) have been de-listed.
6 January 2015 by Margaret Labban
US President Barack Obama issued an executive order and national strategy to combat antibiotic resistance in September 2014,...
29 December 2014 by Kavita Rainova
In early November a bill was put in front of the British parliament, for second reading, proposing that new licences should be...
16 June 2014 by Cameron Lockwood
23 March 2012 by Milena Izmirlieva
About the Life Sciences BlogIndustry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence. IHS Markit Blog Home »
Tweets by @IHS4LifeScience